Diagnostic Value of Interferon-Gamma Release Assay in the Diagnosis of Tuberculosis Infection Before the Use of TNF-Alpha Blocker in Pediatric Rheumatology Patients

Diagnostic Value of Interferon-Gamma Release Assay in the Diagnosis of Tuberculosis Infection Before the Use of TNF-Alpha Blocker in Pediatric Rheumatology Patients

Material and Methods: In this study, 93 pediatric patients with chronic rheumatic inflammatory disease, who would be started on anti-TNF therapy and investigated for latent tuberculosis infection, and 69 control patients without chronic disease, who were examined for any reason, were retrospectively...

Full description

Saved in:
Bibliographic Details
Published in:Çocuk enfeksiyon dergisi Vol. 17; no. 3; pp. 166 - 173
Main Authors: Çetin, Fatma Tuğba, Kocabaş, Emine, Özgür Gündeşlioğlu, Özlem, Çay, Ümmühan, Ufuk Altıntaş, Derya, Özcan, Dilek, Soyupak, Süreyya, Totik, Nazlı, Ünal, İlker
Format: Journal Article
Language:English
Published: Istanbul Aves Yayincilik Ltd. STI 01-09-2023
Subjects:
Antigens
Chronic illnesses
Drugs
Immunization
Infections
Inflammatory diseases
Interferon
Pathogenesis
Patients
Pediatrics
Rheumatology
Tuberculosis
Tumor necrosis factor-TNF
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Material and Methods: In this study, 93 pediatric patients with chronic rheumatic inflammatory disease, who would be started on anti-TNF therapy and investigated for latent tuberculosis infection, and 69 control patients without chronic disease, who were examined for any reason, were retrospectively analyzed. The use of TNF-α blocking drugs may lead to the inhibition of granuloma formation, resulting in reactivation of latent tuberculosis infection (LTBI) and/or active tuberculosis (1,2). [...]it is recommended that patients with indications for use of TNF-α blockers should be screened forthe risk of developing LTBI (3,4). Especially in countries where the incidence and prevalence of TB is high, LTBI reactivation poses an important problem in the treatment with TNF-α blocking biological agents. [...]LTBI and active TB disease should be excluded before TNF-α blocker therapy is started in this group of patients (14). Materials and Methods Study Group In this study, 93 pediatric patients who were followed up with the diagnosis of chronic rheumatic inflammatory disease in the Department of Pediatric Rheumatology of Çukurova University between March 1, 2007 and June 30, 2019, did not respond to standard treatments and had indications for starting TNF-α blocker therapy (Group 1:
ISSN:1307-1068
1308-5271
DOI:10.5578/ced.20239703